<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02936388</url>
  </required_header>
  <id_info>
    <org_study_id>SirTac2014</org_study_id>
    <nct_id>NCT02936388</nct_id>
  </id_info>
  <brief_title>Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis</brief_title>
  <acronym>SirTac</acronym>
  <official_title>A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Characterisation of effect of SIRT and DSM-TACE as local treatment options for liver
      metastases in patients with advanced uveal melanoma with respect to progression-free survival
      and exploratory comparison of secondary endpoints regarding application, activity, adverse
      effects and impact on quality of life in a randomized study design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized phase II trial to evaluate the effect of transarterial radioembolisation
      with yttrium-90 microspheres (SIRT) and transarterial chemoembolisation with cisplatin
      (DSM-TACE) in patients with liver metastases due to advanced uveal melanoma in terms of
      progression-free survival and multiple secondary endpoints.

      Patients in study arm A will receive transarterial radioembolisation one time only. Patients
      in study arm B will receive transarterial chemoembolisation every 4 to 6 weeks until complete
      tumor devascularisation is observed or disease progression or intolerable toxicity occur. At
      the time of local tumor progression patients will be offered the other treatment respectively
      (either SIRT or DSM-TACE) as part of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregression-free survival (PFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SIRT: Transarterial radioembolisation with Yttrium-90-bearing resin microspheres (SIR-Spheres®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DSM-TACE: Transarterial chemoembolisation with Cisplatin and EmboCept® S starch microspheres (PharmaCept GmbH)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SIRT</intervention_name>
    <description>catheter-based application of radioactive microspheres into the hepatic artery</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Drug: Yttrium-90 microspheres (SIR-Spheres®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DSM-TACE</intervention_name>
    <description>catheter-based application of chemotherapy and degradable starch microspheres into the hepatic artery</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Drug: Cisplatin and EmboCept®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (main):

          -  ECOG Performance Status of 0, 1 or 2

          -  Histologically or cytologically confirmed liver metastases of uveal melanoma

          -  At least one measurable lesion according to RECIST criteria v1.1 determined MRI (if
             contraindications against MRI exist CT with contrast media can is allowed)

          -  Metastases in other sides are allowed if not in need of treatment (e.g. asymptomatic
             bone metastasis without indication for radiation)

          -  Prior treatment with systemic anti-cancer therapy is allowed if terminated ≥ 4 weeks
             prior to study treatment start and recovery from toxicity is achieved

          -  Surgery in general and hepatic surgery in particular (e.g. lobe resection,
             radiofrequency ablation) prior to study enrollment are allowed if realized ≥ 4 weeks
             prior to study enrollment and recovery from surgery is achieved

        Exclusion Criteria (main):

          -  Surgically treatable liver metastases

          -  Previous intraarterial hepatic treatment (e.g. radioembolisation, chemoembolisation,
             intraarterial chemotherapy, isolated or percutaneous hepatic perfusion)

          -  Previous treatment with external liver radiation

          -  Major intrahepatic occlusion of the portal vein and/or tumor infiltration of the
             portal vein

          -  Liver cirrhosis Child-Pugh C

          -  Progressive liver failure

          -  Renale failure, bone marrow insufficiency, coagulopathy

          -  Uncontrolled or severe medical conditions which could impair the ability to
             participate in the trial such as unstable cardiac disease or uncontrolled infection

          -  Other malignancy and/or metastases in need of treatment

          -  Current treatment with any anti-cancer therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Keilholz, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Universitätsmedizin Berlin, Charité Comprehensive Cancer Center (CCCC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Anna Peuker</last_name>
    <phone>+49 30 450 513470</phone>
    <email>caroline-anna.peuker@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sebastian Ochsenreither, Dr. med.</last_name>
    <email>sebastian.ochsenreither@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - University Medicine Berlin, Dept. of Haematology, Medical Oncology and Tumor Immunology, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Anna Peuker</last_name>
      <phone>+49 30 450 513470</phone>
      <email>caroline-anna.peuker@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Sebastian Ochsenreither</last_name>
      <email>sebastian.ochsenreither@charite.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://cccc.charite.de/forschung/klinische_studien/solide_tumorerkrankungen/leber_und_gallentumore_icd10_c22_c24/</url>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Caroline Anna Peuker</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>uveal melanoma</keyword>
  <keyword>liver metastasis</keyword>
  <keyword>chemoembolisation</keyword>
  <keyword>radioembolisation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

